Equities research analysts forecast that Edwards Lifesciences Corp (NYSE:EW) will post earnings of $0.41 per share for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have made estimates for Edwards Lifesciences’ earnings, with the highest EPS estimate coming in at $0.51 and the lowest estimate coming in at $0.30. Edwards Lifesciences posted earnings per share of $0.46 in the same quarter last year, which would suggest a negative year over year growth rate of 10.9%. The company is scheduled to report its next quarterly earnings results on Tuesday, July 28th.

According to Zacks, analysts expect that Edwards Lifesciences will report full-year earnings of $1.65 per share for the current financial year, with EPS estimates ranging from $1.58 to $1.75. For the next financial year, analysts forecast that the company will post earnings of $2.16 per share, with EPS estimates ranging from $1.94 to $2.35. Zacks’ EPS averages are an average based on a survey of research analysts that that provide coverage for Edwards Lifesciences.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. The business had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.03 billion. Edwards Lifesciences had a return on equity of 31.83% and a net margin of 24.71%. The business’s quarterly revenue was up 13.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.44 earnings per share.

Several research firms recently issued reports on EW. Credit Suisse Group cut their target price on Edwards Lifesciences to $88.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 2nd. Deutsche Bank cut their target price on Edwards Lifesciences from $81.67 to $75.00 and set a “hold” rating on the stock in a research report on Wednesday, April 22nd. Wells Fargo & Co downgraded Edwards Lifesciences from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $83.33 to $76.67 in a research report on Tuesday, April 28th. Morgan Stanley cut their target price on Edwards Lifesciences from $83.33 to $83.00 and set an “overweight” rating on the stock in a research report on Monday. Finally, Piper Sandler cut their target price on Edwards Lifesciences from $90.00 to $88.33 and set an “overweight” rating on the stock in a research report on Friday, April 24th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and sixteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $82.52.

Shares of NYSE EW traded up $0.36 during mid-day trading on Thursday, hitting $68.25. The stock had a trading volume of 34,110 shares, compared to its average volume of 3,371,622. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.47 and a current ratio of 3.36. The company has a 50 day moving average of $109.88 and a two-hundred day moving average of $82.02. Edwards Lifesciences has a twelve month low of $51.51 and a twelve month high of $82.55. The firm has a market cap of $41.60 billion, a PE ratio of 38.94, a PEG ratio of 2.53 and a beta of 0.84.

In related news, CFO Scott B. Ullem sold 26,700 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $69.51, for a total transaction of $1,855,917.00. Following the completion of the transaction, the chief financial officer now owns 27,114 shares in the company, valued at approximately $1,884,694.14. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Catherine M. Szyman sold 1,116 shares of the company’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $216.91, for a total transaction of $242,071.56. Following the transaction, the vice president now owns 14,755 shares of the company’s stock, valued at approximately $3,200,507.05. The disclosure for this sale can be found here. Over the last three months, insiders have sold 194,323 shares of company stock worth $25,124,106. Corporate insiders own 1.48% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Columbia Trust Co 01012016 raised its position in shares of Edwards Lifesciences by 1.1% during the 1st quarter. Columbia Trust Co 01012016 now owns 4,264 shares of the medical research company’s stock worth $803,000 after purchasing an additional 47 shares during the last quarter. AIA Investment Management Private Ltd raised its position in Edwards Lifesciences by 6.3% during the first quarter. AIA Investment Management Private Ltd now owns 873 shares of the medical research company’s stock valued at $165,000 after acquiring an additional 52 shares in the last quarter. Valeo Financial Advisors LLC raised its position in Edwards Lifesciences by 12.1% during the first quarter. Valeo Financial Advisors LLC now owns 528 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 57 shares in the last quarter. Cedar Brook Financial Partners LLC raised its position in Edwards Lifesciences by 2.3% during the first quarter. Cedar Brook Financial Partners LLC now owns 2,529 shares of the medical research company’s stock valued at $477,000 after acquiring an additional 57 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its position in Edwards Lifesciences by 1.5% during the first quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 4,144 shares of the medical research company’s stock valued at $782,000 after acquiring an additional 63 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: How are Outstanding Shares Different from Authorized Shares?

Get a free copy of the Zacks research report on Edwards Lifesciences (EW)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.